Trials that use: Interim analysis / alpha spending
New to this method? Read the tutorial →
11,819 results
- CGRP, Estrogen, Cortisol, VIP, α-Amylase, PGE2, PGI2 and ß-Endorphin Levels in Menstrual Migraine Before and After Treximet: Complete Statistical AnalysisIndependent statistical analysis of CGRP, Estrogen, Cortisol, VIP, α-Amylase, PGE2, PGI2 and ß-Endorphin Levels in Menstrual Migraine Before and After Treximet: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- ChAIndependent statistical analysis of Varenicline (Chantix™) for the Treatment of Alcohol Dependence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00705523).
- Chairless Chair Exoskeleton. Work-physiological-biomechanical Analysis of the Lower Extremities: Complete Statistical AnalysisIndependent statistical analysis of Chairless Chair Exoskeleton. Work-physiological-biomechanical Analysis of the Lower Extremities: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03134144).
- CHALLENGEIndependent statistical analysis of Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer: primary endpoint results, effect estimate…
- Challenge Dose of Hepatitis B Vaccine in Subjects Who Previously Received Engerix™-B Vaccine: Complete Statistical AnalysisIndependent statistical analysis of Challenge Dose of Hepatitis B Vaccine in Subjects Who Previously Received Engerix™-B Vaccine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- CHAMPIndependent statistical analysis of Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02918292).
- CHAMPSIndependent statistical analysis of Connected Health Blood Pressure Monitoring In Stroke and TIA Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02450760).
- CHANGE 3Independent statistical analysis of Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Change in Oxygen Consumption Following Inhalation Beta Agonists in Healthy Adults: Complete Statistical AnalysisIndependent statistical analysis of Change in Oxygen Consumption Following Inhalation Beta Agonists in Healthy Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- CHANGE2Independent statistical analysis of Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer: primary endpoint results, effect estimate with confidence…
- Changes in Lipids and Lipoproteins in HIV Infected Women After Switch From Protease Inhibitor to Raltegravir: Complete Statistical AnalysisIndependent statistical analysis of Changes in Lipids and Lipoproteins in HIV Infected Women After Switch From Protease Inhibitor to Raltegravir: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Changes in Subjects With Posterior Capsule Tightness: Complete Statistical AnalysisIndependent statistical analysis of Changes in Subjects With Posterior Capsule Tightness: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02353442).
- Changes in the Risk Factors of Coronary Heart Disease Observed After Scaling and Root Planing: Complete Statistical AnalysisIndependent statistical analysis of Changes in the Risk Factors of Coronary Heart Disease Observed After Scaling and Root Planing: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Changes of Pain and Functional Parameters in Back Pain Patients Over Time: Complete Statistical AnalysisIndependent statistical analysis of Changes of Pain and Functional Parameters in Back Pain Patients Over Time: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Changes of Soft and Hard Tissues After Alveolar Ridge Preservation: Freeze-dried Bone Allograft vs. L-PRF Clot: Complete Statistical AnalysisIndependent statistical analysis of Changes of Soft and Hard Tissues After Alveolar Ridge Preservation: Freeze-dried Bone Allograft vs. L-PRF Clot: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- ChangHER-SCIndependent statistical analysis of Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Changing Lifestyles for Better Health: Complete Statistical AnalysisIndependent statistical analysis of Changing Lifestyles for Better Health: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00848757).
- Chantix for Treating Cocaine Dependence: Complete Statistical AnalysisIndependent statistical analysis of Chantix for Treating Cocaine Dependence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00567008).
- Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio+Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database Study: Complete Statistical AnalysisIndependent statistical analysis of Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio+Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database…
- Characteristics of Empagliflozin Initiators: Complete Statistical AnalysisIndependent statistical analysis of Characteristics of Empagliflozin Initiators: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03050619).
- Characteristics of Sleep Patterns in Young Adults With and Without Insomnia: Complete Statistical AnalysisIndependent statistical analysis of Characteristics of Sleep Patterns in Young Adults With and Without Insomnia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Characterization of Dermal Reactions in Pediatric Patients With ADHD Using DAYTRANA: Complete Statistical AnalysisIndependent statistical analysis of Characterization of Dermal Reactions in Pediatric Patients With ADHD Using DAYTRANA: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Characterization of Myocardial Blood Flow Measurements Using Lexiscan®™ (Regadenoson) (Lexiscan®™) Rubidium-82 Myocardial Perfusion PET: A Temporal-Dependency Investigation: Complete Statistical AnalysisIndependent statistical analysis of Characterization of Myocardial Blood Flow Measurements Using Lexiscan®™ (Regadenoson) (Lexiscan®™) Rubidium-82 Myocardial Perfusion PET: A Temporal-Dependency Investigation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Characterization of the Analgesic Effect of CBD in Healthy, Normal Volunteers: Complete Statistical AnalysisIndependent statistical analysis of Characterization of the Analgesic Effect of CBD in Healthy, Normal Volunteers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- CHARGEIndependent statistical analysis of Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- CHARM2Independent statistical analysis of Enhancing Male Participation in Interventions to Prevent Unintended Pregnancy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03514914).
- CHARMSIndependent statistical analysis of Multivirus-specific T Cells for the Treatment of Virus Infections After Stem Cell Transplant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- CHASE 3Independent statistical analysis of A 12-Week Study in Asthmatic Children Ages 6 to
- Check It! Positive Psychology Intervention to Improve Adherence in Adolescents With T1D: Complete Statistical AnalysisIndependent statistical analysis of Check It! Positive Psychology Intervention to Improve Adherence in Adolescents With T1D: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- CheckMate 066Independent statistical analysis of Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- CheckMate 069Independent statistical analysis of Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma: primary endpoint results, effect estimate with confidence interval,…
- CheckMate 384Independent statistical analysis of A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer…
- CheckMate 451Independent statistical analysis of An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based…
- CheckMate 498Independent statistical analysis of An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer): primary endpoint results, effect…
- CheckMate 647Independent statistical analysis of A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- CheckMate 651Independent statistical analysis of Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma…
- CheckMate 744Independent statistical analysis of A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment: primary endpoint…
- CheckMate 7DXIndependent statistical analysis of A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- CheckMate 800Independent statistical analysis of An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence…
- CheckMate 8HWIndependent statistical analysis of A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC):…
- CheckMate 907Independent statistical analysis of Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- CheckMate 908Independent statistical analysis of A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS)…
- CheckMate 914Independent statistical analysis of A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney: primary endpoint…
- CheckMate153Independent statistical analysis of A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen:…
- CheckMate743Independent statistical analysis of Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients: primary endpoint results, effect estimate with confidence…
- Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation in Advanced Metastatic Disease: Complete Statistical AnalysisIndependent statistical analysis of Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation in Advanced Metastatic Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia: Complete Statistical AnalysisIndependent statistical analysis of Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver: Complete Statistical AnalysisIndependent statistical analysis of Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01545141).